Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afamelanotide + NB-UVB
- Development stage
- Unknown
- Lead developer
- Clinuvel Pharmaceuticals
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous (afamelanotide Implant), Topical (nb-uvb Via Phototherapy Device/skin Exposure)
01
Overview
Afamelanotide + NB-UVB is a **combination therapy** for vitiligo consisting of subcutaneous afamelanotide implant (a synthetic analog of alpha-melanocyte-stimulating hormone) and narrowband ultraviolet B (NB-UVB) phototherapy. Afamelanotide acts as a **melanocortin-1 receptor agonist**, stimulating melanocytes to produce eumelanin and promoting melanocyte differentiation and proliferation, while NB-UVB phototherapy suppresses local autoimmune inflammation and stimulates melanocyte regrowth. Randomized controlled trials have shown the combination yields faster and more significant repigmentation, particularly in patients with darker skin types (Fitzpatrick IV-VI), than NB-UVB alone, with acceptable safety. Common adverse effects are erythema, diffuse hyperpigmentation, nausea, and local implant reactions.
- Brand names
- Scenesse
- Other names
- afamelanotide and narrowband ultraviolet B phototherapyafamelanotide plus NB-UVBafamelanotide implant and NB-UVB
02
Targets
MC1R (Melanocortin Type 1 Receptor)
Beyond the preview
Go deeper on afamelanotide + NB-UVB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afamelanotide + NB-UVB.